
CLAIMS

What is claimed is:


1. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ an amount of from about 0.01 mg to about 5 mg per day of the~~a~~ compound is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


2. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of ~~a~~ the compound in combination with (ii) an anti-CD20 antibody is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


3. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of the~~a~~ compound in combination with (ii) an histone deacetylase (HDAC) inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


4. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of the~~a~~ compound in combination with (ii) a proteasome inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

5. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of the~~a~~ compound in combination with (ii) an anti-CD38 antibody is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A




Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

6. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of the~~a~~ compound in combination with (ii) an


anti-SLAMF7 antibody is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


7. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of the~~a~~ compound in combination with (ii) a nuclear export inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


8. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of the~~a~~ compound in combination with (ii) a BCL-2 inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

9. Use of a compound in the manufacture of a medicament for~~A method of~~ treating or managing cancer, wherein ~~comprising administering to a patient in need of such treatment or management~~ (i) a therapeutically effective amount of a compound in combination with (ii) an immune checkpoint inhibitor is to be administered to a patient in need of such treatment or management, wherein the compound is Compound A



Compound A

or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

10. The use~~method~~ of any one of claims 1 to 9, wherein the cancer is non-Hodgkin lymphoma (NHL).

11. The use~~method~~ of claim 10, wherein the NHL is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), or primary central nervous system lymphoma (PCNSL).

~~12. The method of claim 11, wherein the NHL is DLBCL.~~

~~13. The method of claim 11, wherein the NHL is FL.~~

~~14. The method of claim 11, wherein the NHL is MZL.~~

~~15. The method of claim 11, wherein the NHL is MCL.~~

~~16. The method of claim 11, wherein the NHL is PTCL.~~

~~17. The method of claim 11, wherein the NHL is PCNSL.~~

~~18.~~12. The use~~method~~ of claim 10, wherein the NHL is relapsed or refractory NHL.

~~19.~~13. The use~~method~~ of claim 12~~18~~, wherein the NHL is

(a) relapsed or refractory DLBCL;

(b) relapsed or refractory FL;

(c) relapsed or refractory MZL;

(d)relapsed or refractory MCL;

(e) relapsed or refractory PTCL; or

(f) relapsed or refractory PCNSL.

~~20. The method of claim 18, wherein the NHL is relapsed or refractory FL.~~

~~21. The method of claim 18, wherein the NHL is relapsed or refractory MZL.~~

~~22. The method of claim 18, wherein the NHL is relapsed or refractory MCL.~~

~~23. The method of claim 18, wherein the NHL is relapsed or refractory PTCL.~~

~~24. The method of claim 18, wherein the NHL is relapsed or refractory PCNSL.~~

~~25.~~14. The use~~method~~ of claim 12 or 13 ~~any one of claims 18 to 24~~, wherein the subject has failed at least one prior therapy.

~~26. The method of any one of claims 1 to 17, wherein the NHL is newly diagnosed.~~

~~27.~~15. The use~~method~~ of any one of claims 1 to 9, wherein the cancer is Hodgkin Lymphoma (HL), particularly wherein the HL is classical Hodgkin Lymphoma (cHL), and/or wherein the HL is relapsed or refractory HL, wherein particularly the HL is relapsed or refractory cHL, and/or wherein the subject has failed at least one prior therapy.

~~28. The method of claim 27, wherein the HL is classical Hodgkin Lymphoma (cHL).~~

~~29. The method of any one of claims 27 to 28, wherein the HL is relapsed or refractory HL.~~

~~30. The method of claim 29, wherein the HL is relapsed or refractory cHL.~~

~~31. The method of any one of claims 29 to 30, wherein the subject has failed at least one prior therapy.~~

~~32.~~16. The use~~method~~ of any one of claims 1 to 11 and 15~~27 to 28~~, wherein the NHL or HL is newly diagnosed.

~~33.~~17. The use~~method~~ of any one of claims 1 to 16~~32~~, wherein the compound is to be~~administered orally.~~
(a) administered orally;

(b) administered in an amount of about 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.45 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.75 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg or 1.9 mg per day; or
(c) administered once daily for 21 days followed by 7 days of rest.

~~34. The method of any one of claims 1 to 33, wherein the compound is administered in an amount of about 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.45 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.75 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg or 1.9 mg per day.~~

~~35. The method of any one of claims 1 to 34, wherein the compound is administered once daily for 21 days followed by 7 days of rest.~~

~~36.~~18. The use~~method~~ of any one of claims 2 and 10 to 17~~35~~, wherein the anti-CD20 antibody is obinutuzumab or rituximab.

~~37.~~19. The use~~method~~ of claim 18~~36~~, wherein ~~obinutuzumab is administered by intravenous infusion.~~
(a) obinutuzumab is to be administered by intravenous infusion, and/or obinutuzumab is to be administered in an amount of about 1000 mg per day, and/or obinutuzumab is to be administered once every 7 days, or once every 4 weeks; or
(b) rituximab is to be administered intravenously, and/or rituximab is to be administered in an amount of about 375 mg/m^2 per day, and/or rituximab is to be administered by subcutaneous infusion, and/or rituximab is to be administered in an amount of about 1400 mg per day, and/or rituximab is to be administered once every 7 days, or once every 4 weeks.

~~38. The method of any one of claims 36 to 37, wherein obinutuzumab is administered in an amount of about 1000 mg per day.~~

~~39. The method of any one of claims 36 to 38, wherein obinutuzumab is administered once every 7 days, or once every 4 weeks.~~

~~40. The method of any one of claims 2 and 10 to 35, wherein the anti-CD20 antibody is rituximab.~~

~~41. The method of claim 40, wherein rituximab is administered intravenously.~~

~~42. The method of any one of claims 40 to 41, wherein rituximab is administered in an amount of about 375 mg/m^2 per day.~~

~~43. The method of any one of claims 40 to 42, wherein rituximab is administered by subcutaneous infusion.~~

~~44. The method of any one of claims 40 to 43, wherein rituximab is administered in an amount of about 1400 mg per day.~~

~~45. The method of any one of claims 40 to 44, wherein rituximab is administered once every 7 days, or once every 4 weeks.~~

~~46.~~20. The use~~method~~ of any one of claims 3 and 10 to 17~~35~~, wherein the HDAC inhibitor is citarinostat (ACY-241), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

~~47.~~21. The use~~method~~ of any one of claims ~~4~~ and 10 to 17~~35~~, wherein the proteasome inhibitor is ~~marizomib (salinosporamide A), or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~
(a) marizomib (salinosporamide A), or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof;
(b) bortezomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof;
(c) carfilzomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof; or
(d) ixazomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

~~48. The method of any one of claims 4 and 10 to 35, wherein the proteasome inhibitor is bortezomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~49. The method of any one of claims 4 and 10 to 35, wherein the proteasome inhibitor is carfilzomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~50. The method of any one of claims 4 and 10 to 35, wherein the proteasome inhibitor is ixazomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~51.~~22. The use~~method~~ of any one of claims 5 and 10 to 17~~35~~, wherein the anti-CD38 antibody is isatuximab or daratumumab.

~~52. The method of any one of claims 5 and 10 to 35, wherein the anti-CD38 antibody is daratumumab.~~

~~53.~~23. The use~~method~~ of any one of claims 6 and 10 to 17~~35~~, wherein the anti-SLAMF7 antibody is elotuzumab.

~~54.~~24. The use~~method~~ of any one of claims 7 and 10 to 17~~35~~, wherein the nuclear export inhibitor is selinexor, or a geometric isomer or a mixture of geometric isomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

~~55.~~25. The use~~method~~ of any one of claims 8 and 10 to 17~~35~~, wherein the BCL-2 inhibitor is venetoclax, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.


~~56.~~26. The use~~method~~ of any one of claims 9 to 17~~35~~, wherein the immune checkpoint inhibitor is pembrolizumab, nivolumab, or ipilimumab.

~~57. The method of any one of claims 9 to 35, wherein the immune checkpoint inhibitor is nivolumab.~~

~~58. The method of any one of claims 9 to 35, wherein the immune checkpoint inhibitor is ipilimumab.~~

~~59.~~27. The use~~method~~ of any one of claims 1 to 26~~58~~, wherein ~~the method further comprises administering~~ dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is also to be administered.

~~60.~~28. The use~~method~~ of any one of claims 1 to 27~~59~~, wherein the compound is Compound A-S




Compound A-S

or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein particularly the compound is a hydrochloride salt of Compound A-S.

~~61. The method of claim 60, wherein the compound is hydrochloride salt of Compound A-S.~~


~~62. A compound for use in a method of treating or managing cancer, wherein the method comprises administering to a patient in need of such treatment or management an amount of from about 0.01 mg to about 5 mg per day of the compound, wherein the compound is Compound A~~



~~Compound A~~

~~or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~63. A compound for use in a method of treating or managing cancer, wherein the method comprises administering to a patient in need of such treatment or management (i) a therapeutically effective amount of the compound in combination with (ii) a second agent, wherein the compound is Compound A~~



~~Compound A~~

~~or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, and~~

~~wherein the second agent is an anti-CD20 antibody, an histone deacetylase (HDAC) inhibitor, a proteasome inhibitor, an anti-CD38 antibody, an anti-SLAMF7 antibody, a nuclear export inhibitor, a BCL-2 inhibitor, or an immune checkpoint inhibitor.~~

~~64. The compound for use of claim 62 or 63, wherein the cancer is non-Hodgkin lymphoma (NHL).~~

~~65. The compound for use of claim 64, wherein the NHL is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), or primary central nervous system lymphoma (PCNSL).~~

~~66. The compound for use of claim 64, wherein the NHL is relapsed or refractory NHL, optionally wherein the NHL is relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MZL, relapsed or refractory MCL, relapsed or refractory PTCL, or relapsed or refractory PCNSL.~~

~~67. The compound for use of claim 66, wherein the subject has failed at least one prior therapy.~~

~~68. The compound for use of claim 62 or 63, wherein the cancer is Hodgkin Lymphoma (HL), wherein optionally the HL is classical Hodgkin Lymphoma (cHL), and/or wherein the HL is relapsed or refractory HL, wherein optionally the HL is relapsed or refractory cHL, and/or wherein the subject has failed at least one prior therapy.~~

~~69. The compound for use of any one of claims 62 to 65 or 68, wherein the NHL or HL is newly diagnosed.~~

~~70. The compound for use of any one of claims 62 to 69, wherein the compound is administered in an amount of about 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.45 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.75 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg or 1.9 mg per day, and/or wherein the compound is administered once daily for 21 days followed by 7 days of rest.~~

~~71. The compound for use of any one of claims 63 to 70, wherein the anti-CD20 antibody is obinutuzumab or rituximab.~~

72. The compound for use of claim 71, wherein a) obinutuzumab is administered by intravenous infusion, and/or wherein obinutuzumab is administered in an amount of about 1000 mg per day, and/or wherein obinutuzumab is administered once every 7 days, or once every 4 weeks, or

b) rituximab is administered intravenously, and/or wherein rituximab is administered in an amount of about 375 mg/m^2 per day, and/or wherein rituximab is administered by subcutaneous infusion, and/or wherein rituximab is administered in an amount of about 1400 mg per day, and/or wherein rituximab is administered once every 7 days, or once every 4 weeks.

73. The compound for use of any one of claims 63 to 70, wherein the HDAC inhibitor is citarinostat (ACY-241), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, or

wherein the proteasome inhibitor is marizomib (salinosporamide A), or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, or

wherein the proteasome inhibitor is bortezomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, or

wherein the proteasome inhibitor is carfilzomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, or

wherein the proteasome inhibitor is ixazomib, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, or

wherein the anti-CD38 antibody is isatuximab, or

wherein the anti-CD38 antibody is daratumumab, or

wherein the anti-SLAMF7 antibody is elotuzumab, or

~~wherein the nuclear export inhibitor is selinexor, or a geometric isomer or a mixture of geometric isomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, or~~

~~wherein the BCL-2 inhibitor is venetoclax, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~74. The compound for use of any one of claims 63 to 70, wherein the immune checkpoint inhibitor is pembrolizumab, nivolumab, or ipilimumab.~~

~~75. The compound for use of any one of claims 62 to 74, wherein the method further comprises administering dexamethasone, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.~~

~~76. The compound for use of any one of claims 62 to 75, wherein the compound is Compound A-S.~~